Such differences underscore that immune checkpoint blockade therapies may require different tailoring for NSCLC than for SCLC, with PD-1/PD-L1 inhibitors potentially being more effective in NSCLC, whereas CTLA-4 inhibitors may better address immune suppression in SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.